Brussels, 26 June 2025 - Against a backdrop of growing geopolitical instability and the objective to improve resilience to external shocks, the EU intends to increase its health autonomy. The EU can rely on the innovative health biotech and pharmaceutical industry which has significant footprint in Europe with high manufacturing capacity and resilient supply-chains, as recognised by the Critical Medicines Alliance.

The market for biologics has been growing consistently and recent years have been characterised as a “golden decade” culminating with biologics representing 44% of the global R&D pipeline in 2024. To answer to market demand, feedstock is essential to ensure a flexible and resilient European industry.

This informative paper provides a snapshot on the topic of feedstock for health biomanufacturing. It explores the topic of feedstock for preparedness and resilience and strategic supply-chains for EU leadership, and presents examples of existing supply-chains from the initial feedstock and biomanufacturing to the product and final application. 

The EU needs to forecast future feedstock demands and assess dependencies, vulnerabilities and risks and build a future-proof policy framework to tackle challenges while exploring technological and industrial opportunities.